Protective Effect of Coronary Collaterals on Infarct Size in Patients With Acute Myocardial Infarction
NCT ID: NCT00412672
Last Updated: 2015-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is further hypothesized that myocardial salvage provided by collateral flow will decrease infarct size and this in turn will decrease LV dilatation post-myocardial infarction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EUROpean Intracoronary Cooling Evaluation in Patients With ST-elevation Myocardial Infarction.
NCT03447834
Positive Effect of Ischemic Postconditioning During Acute Myocardial Infarction
NCT00333320
Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction
NCT00302419
Effect of Permanent Right Internal Mammary Artery Occlusion on Extracardiac Coronary Collateral Supply
NCT03950947
Effects of Coronary Sinus Occlusion on Myocardial Ischemia (Pilot Study)
NCT01625832
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is further hypothesized that myocardial salvage provided by collateral flow will decrease infarct size and this in turn will decrease LV dilatation post-myocardial infarction.
The two primary endpoints are infarct size as assessed by increase of biochemical cardiac markers and coronary collateral perfusion index (CPI) as obtained by transthoracic MCE.
Extent of LV remodelling, i.e., LV dilatation as assessed by serial assessment of LV dimension by LV angiogram and/or echocardiography, respectively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients \> 18 years old of either sex
* Patients who have given informed consent to the study
Exclusion Criteria
* Patients with cardiogenic shock
* Patients with myocardial infarction secondary to occlusion of a recently revascularized vessel (subacute stent thrombosis)
* Patients with severe arrhythmias
* Patients whose door-to-balloon time exceeds 120 minutes
* Pregnancy
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swiss National Science Foundation
OTHER
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Cardiology, University Hospital, CH-3010 Bern, Switzerland
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Seiler, Prof.
Role: PRINCIPAL_INVESTIGATOR
University Hospital Bern, Switzerland
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
37/01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.